{"id":"W2956922351","doi":"10.1158/1078-0432.ccr-19-0298","title":"Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Spinal Cord Injury BC; Canadian Cancer Society; Espace pour la vie","funders":"Innate Pharma","keywords":"Medicine; Nausea; Vomiting; Pharmacodynamics; Internal medicine; Adverse effect; Cohort; Tolerability; Gastroenterology; Cancer; Cervical cancer; Endometrial cancer; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00681255,0.0001733922,0.001106702,0.0002892645,0.0001172123,0.00001715179,0.0002761626,0.000208853,0.0003626941],"category_scores_gemma":[0.001100686,0.0001006521,0.0001570528,0.0009156213,0.0004598754,0.00007795281,0.0001054101,0.000655817,0.000001272975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006002825,"about_ca_system_score_gemma":0.002145933,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.166267,"about_ca_topic_score_gemma":0.3660157,"domain_scores_codex":[0.9953465,0.001279332,0.001255713,0.0005053491,0.001119665,0.0004933936],"domain_scores_gemma":[0.996943,0.001412568,0.0004110415,0.0005721928,0.0004809484,0.000180224],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1372376,0.0009783863,0.8309926,0.0001083007,0.0002340192,0.000003887546,0.0004359082,0.00001625429,0.0003042085,0.000005305254,0.00008359016,0.02959996],"study_design_scores_gemma":[0.1278808,0.009769474,0.8604103,0.0005619153,0.00007279093,2.446798e-7,0.000586656,0.00001551873,0.00009064453,0.00001465865,0.0004921489,0.0001048509],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990427,0.001132774,1.694559e-7,0.00044679,0.000519734,0.007288494,0.00005709333,0.000005716393,0.0001222743],"genre_scores_gemma":[0.9982246,0.000839178,0.00001352088,0.0001467987,0.00008340895,0.0004911795,0.000006788317,0.00002411081,0.0001704609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1997487,"threshold_uncertainty_score":0.8392849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.142373434106831,"score_gpt":0.4662813181220757,"score_spread":0.3239078840152447,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}